Erratum: The role of SRC-3 in human breast cancer (Nature Reviews Clinical Oncology (2010) 7 (8-89)) DOI: 10.1038/nrclinonc.2009.219);The role of SRC-3 in human breast cancer

Nature Reviews Clinical Oncology

Volumn 7, Issue 2, 2010, Pages 83-89

  Gojis, Ondrej ^a,b   Rudraraju, Bharath ^b   Gudi, Mihir ^c   Hogben, Katy ^c   Sousha, Sami ^c   Coombes, Charles R ^b   Cleator, Susan ^b   Palmieri, Carlo ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; EXEMESTANE; MESSENGER RNA; POLYGLUTAMINE; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TRANSCRIPTION FACTOR PAX2;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; INTRADUCTAL CARCINOMA; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SMOKING HABIT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRINUCLEOTIDE REPEAT;

EID: 76449090404     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.34     Document Type: Erratum

References (64)

1. Mangelsdorf, D. J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 835-839 (1995).
2. Tsai, M. J. & O'Malley, B. W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann. Rev. Biochem. 63, 451-486 (1994).
3. McKenna, N. J. & O'Malley, B. W. Minireview: nuclear receptor coactivators-an update. Endocrinology 143, 2461-2465 (2002).
4. Xu, J. & Li, Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol. Endocrinol. 17, 1681-1692 (2003).
5. Isola, J. J. et al. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am. J. Pathol. 147, 905-911 (1995).
6. Guan, X. Y. et al. Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within amplified region at 20q11-q13.2 in breast cancer. Cancer Res. 56, 3446-3450 (1996).
7. Anzick, S. L. et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965-968 (1997).
8. Belandia, B. & Parker, M. G. Functional interaction between the p160 coactivator proteins and the transcriptional enhancer factor family of transcription factors. J. Biol. Chem. 275, 30801-30805 (2000).
9. Chen, S. L., Dowhan, D. H., Hosking, B. M. & Muscat, G. E. The steroid receptor coactivator, GRIP-1, is necessary for MEF-2C-dependent gene expression and skeletal muscle differentiation. Genes Dev. 14, 1209-1228 (2000).
10. Li, C. et al. Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/AIB1 coactivator function and turnover. Mol. Cell. 31, 835-849 (2008).
11. Savkur, R. S. & Burris, T. P. The coactivator LXXLL nuclear receptor recognition motif. J. Pept. Res. 63, 207-212 (2004).
12. Ogryzko, v. v., Schiltz, R. L., Russanova, v., Howard, B. H. & Nakatani, Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87, 953-959 (1996).
13. Teyssier, C., Chen, D. & Stallcup, M. R. Requirement for multiple domains of the protein arginine methyltransferase CARM1 in its transcriptional coactivator function. J. Biol. Chem. 277, 46066-46072 (2002).
14. Spencer, T. E. et al. Steroid receptor coactivator-1 is a histone acetyl transferase. Nature 389, 194-198 (1997).
15. Yi, P. et al. Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1. Mol. Cell 29, 465-476 (2008).
16. Wu, R. C. et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol. Cell 15, 937-949 (2004).
17. Oh, A. S. et al. Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. Mol. Cell. Biol. 28, 6580-6593 (2008).
18. Park, K. J., Krishnan, v., O'Malley, B. W., Yamamoto, Y. & Gaynor, R. B. Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol. Cell 18, 71-82 (2005).
19. Wu, R. C., Smith, C. L. & O'Malley, B. W. Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr. Rev. 26, 393-399 (2005).
20. Wang, Z. et al. Regulation of somatic growth by the p160 coactivator p/CIP. Proc. Natl Acad. Sci. USA 97, 13549-13554 (2000).
21. Xu, J. et al. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc. Natl Acad. Sci. USA 97, 6379-6384 (2000).
22. Kuang, S. Q. et al. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res. 64, 1875-1885 (2004).
23. Tilli, M. T. et al. Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice. Mol. Endocrinol. 19, 644-656 (2005).
24. Torres-Arzayus, M. I. et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6, 263-274 (2004).
25. Dai, P. & Wong, L. J. Somatic instability of the DNA sequences encoding the polymorphic polyglutamine tract of the AIB1 gene. J. Med. Genet. 40, 885-890 (2003).
26. Bevan, C. & Parker, M. The role of coactivators in steroid hormone action. Exp. Cell. Res. 253, 349-356 (1999).
27. Chamberlain, N. L. et al. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22, 3183-3186 (1994).
28. Rebbeck, T. R. et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res. 61, 5420-5424 (2001).
29. Kadouri, L. et al. Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. Int. J. Cancer 108, 399-403 (2004).
30. Hughes, D. J. et al. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene. Int. J. Cancer 117, 230-233 (2005).
31. Spurdle, A. B. et al. The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol. Biomarkers Prev. 15, 76-79 (2006).
32. Haiman, C. A. et al. Polymorphic repeat in AIB1 does not alter breast cancer risk. Breast Cancer Res. 2, 378-385 (2000).
33. Colilla, S. et al. The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis 27, 599-605 (2006).
34. Wasserman, L. et al. Correlates of obesity in postmenopausal women with breast cancer: comparison of genetic, demographic, diseaserelated, life history and dietary factors. Int. J. Obes. Relat. Metab. Disord. 28, 49-56 (2004).
35. Stoll, B. A. Adiposity as a risk determinant for postmenopausal breast cancer. Int. J. Obes. Relat. Metab. Disord. 24, 527-533 (2000).
36. Goodwin, P. J. & Boyd, N. F. Body size and breast cancer prognosis: a critical review of the evidence. Breast Cancer Res. Treat. 16, 205-214 (1990).
37. Kirkegaard, T. et al. Amplified in breast cancer 1 in human epidermal growth factor receptor- positive tumors of tamoxifen-treated breast cancer patients. Clin. Cancer Res. 13, 1405-1411 (2007).
38. Bautista, S. et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin. Cancer Res. 4, 2925-2929 (1998).
39. Iwase, H. et al. Clinical significance of AIB1 expression in human breast cancer. Breast Cancer Res. Treat. 80, 339-345 (2003).
40. Bouras, T., Southey, M. C. & venter, D. J. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res. 61, 903-907 (2001).
41. Murphy, L. C. et al. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res. 60, 6266-6271 (2000).
42. Kurebayashi, J. et al. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin. Cancer Res. 6, 512-518 (2000).
43. Osborne, C. K. et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/ neu in tamoxifen resistance in breast cancer. J. Natl Cancer Inst. 95, 353-361 (2003).
44. List, H. J., Reiter, R., Singh, B., Wellstein, A. & Riegel, A. T. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res. Treat. 68, 21-28 (2001).
45. Hudelist, G. et al. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinomaspecific co-activator. Breast Cancer Res. Treat. 78, 193-204 (2003).
46. Dihge, L. et al. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res. Treat. 109, 255-262 (2008).
47. Harigopal, M. et al. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome. Breast Cancer Res. Treat. 115, 77-85 (2008).
48. Thorat, M. A. et al. Amplified in breast cancer 1 expression in breast cancer. Histopathology 53, 634-641 (2008).
49. Camp, R. L., Chung, G. G. & Rimm, D. L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 8, 1323-1327 (2002).
50. Torchia, J. et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387, 677-684 (1997).
51. Li, L. B., Louie, M. C., Chen, H. W. & Zou, J. X. Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression. Cancer Lett. 261, 64-73 (2008).
52. Bai, J., Uehara, Y. & Montell, D. J. Regulation of invasive cell behavior by taiman, a Drosophila protein related to AIB1, a steroid receptor coactivator amplified in breast cancer. Cell 103, 1047-1058 (2000).
53. Shou, J. et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/ neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 96, 926-935 (2004).
54. Hurtado, A. et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456, 663-666 (2008).
55. Howell, A. et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
56. Coates, A. S. et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25, 486-492 (2007).
57. Coombes, R. C. et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350, 1081-1092 (2004).
58. Boccardo, F. et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J. Clin. Oncol. 23, 5138-5147 (2005).
59. Jakesz, R. et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366, 455-462 (2005).
60. Goss, P. E. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793 - 1802 (2003).
61. Jakesz, R. et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J. Natl Cancer Inst. 99, 1845-1853 (2007).
62. Coombes, C. et al. Intergroup Exemestane Study Pathology Sub-Study. Imperial College London [online], http://www1.imperial.ac.uk/medicine/ about/divisions/sora/oncology/cancer/ccb/ breast-cancer/iccg/pathies/(2009).
63. Dowsett, M. et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J. Clin. Oncol. 26, 1059-1065 (2008).
64. viale, G. et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrineresponsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J. Clin. Oncol. 26, 5569-5575 (2008).